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Abstract
Background: ABCG2 is an ABC transporter. It has been demonstrated that endogenous ABCG2 expression in
certain cancers is a possible reflection of the differentiated phenotype of the cell of origin and likely contributes to
intrinsic drug resistance. But little is known about the contribution of ABCG2 to the drug resistance and the
clinicopathological characteristics in breast cancer. In the present study, we investigated the expression of ABCG2
and the correlations between ABCG2 expression and patients’ clinicopathological and biological characteristics.
Methods: Immunohistochemistry was employed on the tissue microarray paraffin sections of surgically removed
samples from 196 breast cancer patients with clinicopathological data.
Results: The results showed that ABCG2 was expressed in different intensities and distributions in the tumor cells
of the breast invasive ductal carcinoma. A positive stain for ABCG2 was defined as a brown stain observed in the
cytoplasm and cytomembrane. A statistically significant correlation was demonstrated between ABCG2 expression
and HER-2 expression (p = 0.001), lymph node metastasis (p = 0.049), and clinical stage (p = 0.015) respectively.
Conclusion: ABCG2 correlated with Her-2 expression, lymph node metastasis and clinical stage in breast invasive
ductal carcinoma. It could be a novel potential bio-marker which can predict biological behavior, clinical
progression, prognosis and chemotherapy effectiveness.
Keywords: ABCG2(BCRP), Her-2, Lymph node metastasis, Clinical stage, Correlation, Breast invasive ductal cancer,
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Background
Breast cancer is the most common carcinoma in females
and the second most common cause of cancer related
mortality in women [1], with more than 1,000,000 new
cases and 370,000 deaths yearly worldwide [2]. Surgery is
the mainstay of the treatment of breast cancer. Many
patients receive adjuvant (post-operative) therapy, which
reduces the risk of loco-regional and distant disease
recurrence. Adjuvant treatment options include che-
motherapy, radiotherapy, endocrine therapy and biologi-
cal agents, aiming to provide maximum survival benefit
with minimum toxicity [3]. Systemic therapy improves
t h ed i s e a s e - f r e es u r v i v a lo ft hose patients, but does not
cure patients with advanced or metastatic disease, and
fails to benefit the majority of patients with localized
breast cancer. Intrinsic resistance to chemotherapy is
emerging as a significant cause of treatment failure [4]
and the resistance phenotype is often associated with
increased expression of ATP-binding cassette (ABC)
transporters that mediate energy-dependent transport of
substrate drugs out of the cella g a i n s tac o n c e n t r a t i o n
gradient [5]. ABCG2 (ATP-binding cassette sub-family G
member 2), or breast cancer resistance protein (BCRP), is
an ABC transporter that has been extensively studied. Its
overexpression has been demonstrated that endogenous
ABCG2 expression in certain cancers is possibly a reflec-
tion of differentiated phenotype of cell origin and may
contribute to intrinsic drug resistance in vitro. Notably,
research into the transporter’s role in cancer drug resis-
tance and its development as a therapeutic target in
cancer has lagged [6]. The data about the contribution of
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[7-9]. Therefore, further studies are needed to explore
the expression of ABCG2 in primary breast cancer and
its correlation with the clinicopathological and biological
characteristics of the breast cancer.
In the present study, the expression of ABCG2 was
investigated by immunohistochemistry using tissue micro-
array according to immunohistochemical phenotypes and
the correlationships between ABCG2 expression and the
clinicopathological data. Moreover, biological characteris-
tics were discussed. We demonstrated a possibility of its
predictive role in chemotherapy in breast cancer.
Materials and methods
Patients and Tissue samples
We retrieved tissue samples from patients with breast
invasive ductal carcinoma in the Department of Pathology
of Qilu Hospital of Shandong University during July 2007
through December 2008. Formalin-fixed and paraffin-
embedded tissue specimens from 196 patients with
primary breast cancer were included. All archival hema-
toxylin and eosin (H&E)-stained slides for each patient
were reviewed by two pathologists. For the usage of the
clinical materials for research purposes, prior patient con-
sent and approval from the Institutional Research Ethics
Committee were obtained. All the diagnoses were made
following the Pathology and Genetics of Tumors of Breast
of the World Health Organization Classification of
Tumors [10]. Clinicopathologic classification and staging
were determined according to the American Joint Com-
mittee on Cancer criteria [11].
The histological grade was assessed using the Notting-
ham grading system [12], and nuclear grade was evaluated
according to the modified Black’s nuclear grade [13]. His-
tological parameters such as histological subtype, nuclear
grade and histological grade were evaluated according to
H&E-stained slides. Clinical parameters included patients’
age, tumor size, lymph node status, clinical stage and bio-
logical markers (ER, PR, HER2 and ki67 et al).
Tissue microarray
For each H&E-stained slide, two representative areas were
selected and the corresponding spots were marked on the
surface of the paraffin block. Using a tissue microarray
punching instrument, the selected areas were punched out
and were placed into the recipient block side by side. Each
tissue core was 2 mm in diameter and was assigned with a
unique tissue microarray location number that was linked
to a database containing other clinicopathologic data.
Immunohistochemistry (IHC)
The streptavidin-peroxidase-biotin (SP) immunohisto-
chemical method was utilized to study the expression of
ABCG2 in 196 paraffin-embedded breast tissues.
In brief, paraffin-embedded specimens were cut into
4 μm sections and baked at 60°C for 60 min. The sections
were deparaffinized with xylenes and rehydrated. Then
sections were submerged into EDTA antigenic retrieval
buffer in a pressure cooker for 10 minutes and then
cooled at room temperature for 20 minutes. The sections
were treated with 3% hydrogen peroxide in methanol to
quench the endogenous peroxidase activity, followed by
incubation with normal serum to block nonspecific bind-
ing. Mouse monoclonal [BXP-21] (1:50; Abcam Com-
pany, ab3380, USA) was incubated with the sections
overnight at 4°C; the second antibody was from an SP
reagent kit (Zhongshan Biotechnology Company, Beijing,
China). After washing, the tissue sections were treated
with biotinylated anti-mouse secondary antibody, fol-
lowed by further incubation with streptavidin-horserad-
ish peroxidase complex for 20 mins. Stained with
diaminobenzidine (DAB), the sections were counter-
stained with hematoxylin. For negative controls, the anti-
ABCG2 antibody was replaced with PBS.
Evaluation of Immunohistochemical Staining
The stained slides were reviewed and scored indepen-
dently by two observers blinded to the patients’ informa-
tion, and the scores were determined by combining the
proportion of positively stained tumor cells and the inten-
sity of staining. Tumor cell proportion was scored as fol-
lows [14]: 0 (no positive tumor cells); 1 (≤ 30% positive
tumor cells); 2 (31-50% positive tumor cells); 3 (51-80%
positive tumor cells) and 4 (> 80% positive tumor cells).
Staining intensity was graded according to the following
criteria: 0 (-, no staining); 1 (+, weak staining = light
yellow); 2 (++, moderate staining = yellow brown) and 3
(+++, strong staining = brown). Staining index (SI) was
calculated as the product of the staining intensity score
and the proportion of positive tumor cells. Using this
method of assessment, we evaluated ABCG2 expression in
invasive breast cancer cells by determining the SI, with
scores of 0,1, 2, 3, 4, 6, 9 or 12. The optimal cutoff value
for high and low expression level was identified: an SI
score of ≥ 4 was used to define tumors with high ABCG2
expression, and an SI score of ≤ 3 was used to indicate
low ABCG2 expression and the SI score of 0 was used to
imply negative expression.
Statistical Analysis
Analyses were performed using the statistical software
package SPSS 13.0 (SPSS, Chicago, IL). The chi-square
test or Fisher’s exact test were used to evaluate the cor-
relation between ABCG2 expression and the clinico-
pathologic characteristics if appropriate. Bivariate
correlations between study variables were calculated by
Spearman’s rank correlation coefficients. Differences
were considered statistically significant for p < 0.05.
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The specificity of the immunodetection was confirmed
by using the monoclonal antibodies BXP-21. A positive
stain for ABCG2 was defined as a brown stain observed
in the cytoplasm and cytomembrane. Positive staining of
normal adjacent ductal epithelia as well as vascular
endothelium of the breast has a low level expression
(Figure 1). And it can serve as an internal positive con-
trol. No staining of lymphoid cells was seen.
In the cells of the breast invasive ductal carcinoma,
ABCG2 expression was present in different intensities
and different cell distributions. Following the staging cri-
teria of stain intensity, 15 cases (7.7%) were identified as
completely negative (Figure 2), 80 cases (40.8%) were
identified as “+” (Figure 3), 77 cases (39.2%) were identi-
fied as “++” (Figure 4), and 24 cases (12.3%) were identi-
fied as “+++” (Figure 5). According to the above
assessment methods and evaluation criterion, combining
the proportion of positively stained tumor cells, the high
level, low level and negative expression of ABCG2 was
observed in 73 cases (37.2%), 97 cases (49.5%) and 26
cases (13.3%), respectively.
There was no significant correlation between the
expression level of ABCG2 and biological factors such
as patients’ age (p = 0.801), histology type (p = 0.711),
histology-grade (p = 0.424), tumour size (p = 0.210), ER
(p = 0.136), PR (p = 0.693) and Ki67 (p = 0.906). In
contrast, statistical analyses indicated that ABCG2
expression was positively related with HER-2 expression
and the correlation was statistically significant (p =
0.001); meanwhile, the correlation between ABCG2
expression and lymph node metastasis/clinical stage was
significant (p = 0.049/0.015, respectively). The results of
these analyses are summarized in Table 1.
Discussion
ABCG2, or breast cancer resistance protein (BCRP), is the
second member of the G subfamily of the ATP-binding
cassette (ABC) efflux transporter superfamily that has
been the subject of intense study since its discovery two
decades ago. In 1998, Doyle et al. cloned the gene respon-
sible for the novel resistance phenotype from the MCF-7
A d r / V ps u b l i n ei nt h ea b s e n c eo fP - g po rM R P 1 .T h e y
named the gene BCRP for breast cancer resistance protein
since it was cloned from a breast cancer subline. Soon
after, two nearly identical transporters, termed ABCP for
the ABC transporter highly expressed in placenta [15] and
MXR for the mitoxantrone resistance gene[16], were
found in different labs. When the sequences for the genes
BCRP/ABCP/MXR became available, they proved to be
nearly identical. The Human Genome Nomenclature
Committee assigned the gene the name ABCG2, making it
Figure 1 Normal breast tissue, ABCG2 positive (IHC, SP ×200).
The ABCG2 staining is weak, and mainly localized in the cytoplasm
and cytomembrane of the glandular epithelium cells.
Figure 2 Breast cancer tissue, ABCG2 negative (IHC, SP ×200).
The ABCG2 staining is almost negative.
Figure 3 Breast cancer tissue, ABCG2 positive + (IHC, SP ×200).
The ABCG2 staining is weak.
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that is made up of only half-transporters.
The human ABCG2 gene is localized on chromosome 4,
band 4q21-4q22 in normal cells [17]. It extends over 66 kb
containing 16 exons and 15 introns, and the resulting pro-
tein is 655 amino acids long [18]. The development of
antibodies to ABCG2 enabled the detection of ABCG2 in
formalin-fixed, paraffin-embedded tissues. Maliepaard et
al. examined ABCG2 expression in normal tissues using
the BXP-21 and BXP-34 monoclonal antibodies. ABCG2
expression was found in placenta, particularly in the sync-
tiotrophoblastic cells, as well as in colon, small intestine,
biliary canaliculi, breast tissue, venous endothelium, and in
capillaries [19].
In the present study, we studied ABCG2 expression in
paraffin-embedded tumor samples using the IHC method
with the BXP-21 antibody, and the positive stain for
ABCG2 is located in the cytoplasm and cytomembrane of
cells as the product leaflet of the antibody indicates. The
expression of ABCG2 in the normal mammary glandular
epithelia and in the stromal cells is consistent with pre-
vious literature.
In solid tumors, Diestra et al. studied ABCG2 expression
in paraffin-embedded tumor samples with the BXP-21
antibody and reported frequent expression in tumors of
the digestive tract, endometrium, lung and melanoma [20].
Breast cancer has been most extensively studied, with most
reports concluding that ABCG2 expression was relatively
low and did not appear to correlate with clinical outcome
in the studies of Kanzak et al. [7] or Faneyte et al. [8].
Figure 4 Breast cancer tissue, ABCG2 positive ++ (IHC, SP
×200). The ABCG2 staining is moderate.
Figure 5 Breast cancer tissue, ABCG2 positive +++ (IHC, SP
×200). The ABCG2 staining is strong.
Table 1 The correlation between the expression of BCRP
and the clinicopathological parameter
Patients BCRP expression P value
n (%) negative low high
Age 0.801
≤ 50 years 80 10 38 32
> 50 years 116 16 59 41
Histology-type 0.711
IDC 155 20 75 60
IDC with others 41 6 22 13
Histology-grade 0.424
G1/G2 143 19 67 57
G3 53 7 30 16
Tumour size 0.210
≤ 2.0 cm 97 9 48 40
> 2.0 cm 99 17 49 33
LNM 0.049*
- 103 8 56 39
+9 3 1 8 4 1 3 4
ER 0.136
-/+ 96 14 53 29
++/+++ 100 12 44 44
PR 0.693
-/+ 128 18 65 45
++/+++ 68 8 32 28
HER2 0.001*
-/+ 138 18 57 63
++/+++ 58 8 40 10
Ki67 0.906
Positive ≤ 50% 154 21 75 58
Positive > 50% 42 5 22 15
Clinical stage 0.015*
Stage I 60 2 32 26
Stage IIa and IIb 86 11 44 31
StageIIIa and IIIb 50 13 21 16
P values were evaluated by chi-square test or the Fisher’s exact test. *P < 0.05.
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expression of ABCG2 in most tumor cells (86.7%) of the
breast invasive ductal carcinoma is positive, in which
about 40% cases present relatively high ABCG2 expres-
sion in the breast cancer cells. Furthermore, the expres-
sion of ABCG2 is correlated with the expression of
HER2 significantly (p = 0.001) by means of statistic ana-
lysis of 196 breast cancer cases detected by IHC. Those
patients with high expression of ABCG2 were demon-
strated to be more frequently showing high immunor-
eactions with HER2, which suggests that ABCG2 may
have some correlation with worse biological behavior
and clinical aggressiveness. Besides, the expression of
ABCG2 is correlated with lymph node metastasis (p =
0.049) and clinical stage (p = 0.015), which suggests that
the patients with high expression of ABCG2 may have a
worse prognosis than those with low expression of
ABCG2.
In the previous reports, much fewer cases (43 cases
and 52 cases, respectively) were examined than that in
the present study (196 cases). They mainly detected the
levels of BCRP mRNA in those cases, and only 27 cases
of breast cancer underwent IHC testing to examine the
expression of BCRP protein [7,8]. These may explain the
differences between their studies and the present one.
To the best of our knowledge, this is the first report
that the expression of ABCG2 is correlated with some
clinicopathological parameters and biological markers in
the cohort of breast invasive ductual carcinoma. We
think it is of great importance for further research.
As we all know, HER2 is an oncogene that has been
studied extensively. Human epidermal growth factor
receptor 2 (ERBB2, formerly HER2/neu, c-erbB2), 1 of a
family of 4 membrane tyrosine kinases (TKs), was found
to be amplified in a human breast cancer cell line 26
years ago [21], and this amplification was shown to be
important in the pathogenesis and progression of human
breast cancer [22]. Since that time, HER2 amplification
and resultant HER2 protein overexpression have been
linked to important tumor cell proliferation and survival
pathways, several drugs have been developed to target
the pathway, and the detection of HER2 has become a
routine prognostic and predictive factor in breast cancer
[23].
Normal tissues have a low complement of HER2 mem-
brane protein. Overexpression of HER2 is seen in 20% of
breast cancers, and it confers worse biological behavior
and clinical aggressiveness in breast cancer [22,24]. The
differential in HER2 expression between normal tissues
and tumors helps to define HER2 as an ideal treatment
target. Trastuzumab, the first treatment targeting HER2,
is well tolerated in patients and has little toxicity because
its effects are relatively specific for cancer cells over
expressing HER2.
Thus, the significant correlation (p = 0.001) between the
expression of ABCG2 and of HER2 may suggest that
ABCG2 is not only an ABC transporter which plays a role
in drug-resistance of breast cancer chemotherapy but also
a novel potential bio-marker which can predict biological
behavior, clinical progression, prognosis and chemother-
apy effectiveness. And it indicates that when the tumors
are treated with chemotherapy and targeting medicines,
the antagonists of ABCG2 are supposed to be applied
together.
Because the activated AKT mediates the metastasis of
tumor cells by the HER2/PI3K/PTEN/AKT pathway [25],
HER2 has direct correlation with lymph node metastasis
of breast cancer. Due to the strong correlation between
the expression of ABCG2 and of HER2, it is easy to
understand the correlation between ABCG2 and lymph
node metastasis status (p = 0.049) found in this study.
Clinical stage is dependent on the lymph node metastasis
in large extent, and the correlation between them is
obvious. So the significant correlation (p = 0.015)
between the expression of ABCG2 and clinical stage
found in the present study is pleasant to be accepted by
us. Because there was no case in clinical IV stage in the
196 patients which were used in the study, it is not possi-
ble to evaluate the correlation between ABCG2 expres-
sion and cases with distant metastasis.
Two functional elements in the ABCG2 promoter, the
estrogen [26] and hypoxia [27] response elements, and a
peroxisome proliferator-activated receptor g (PPARg)
response element upstream of the ABCG2 gene [28] have
been shown to control ABCG2 expression. So it seems
that the expression of ER should be correlated with
ABCG2, but the result of our study failed to show this. It
is not disappointing, because previous studies have
showed that the effects of E2 on ABCG2 expression in
breast cancer cells were inconsistent and tissue-specific
as a result of the differences between ERaand ERb.I n
several human breast cancer cell lines, E2 exposure
decreases BCRP protein expression and function, but it
does this by acting through ERaand not ERb[29]. How-
ever, E2 has also been reported to increase BCRP protein
expression in a human breast cancer cell line by signaling
through ERa[30]. In a human placenta cell line, E2 sig-
naled through ERb to up-regulate BCRP [31]; and Anika
M S Hartz et al. found that E2 signals through ERb,
PTEN/PI3K/Akt/GSK3 to down-regulate the expression
o fB C R P[ 3 2 ] .T h u s ,b o t hE R aand ERb can be involved
in E2 regulation of BCRP, but the signals involved and
the effect on BCRP (up- or down-regulation) seem to be
inconsistent and tissue-specific. These may be the reason
why the correlation between ABCG2 and ER is not sig-
nificant (p = 0.136).
As to the possible regulation signaling pathway between
HER2 and ABCG2, we speculate some possibilities below.
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PI3K/Akt signaling regulates ABCG2 activity in mouse
and human gliomas [33], and PTEN/PI3K/AKT pathway
has already been confirmed be one of the signal-transmit-
ting pathways in the HER signaling network. HER2 part-
ners with HER3 to form heterodimerization, and HER3
has multiple docking sites for PI3K. So, HER2 partnering
with HER3 is the most potent stimulator of the PI3K/AKT
pathway [27].
The HER2/PTEN/PI3K/AKT/ABCG2 pathway may be
the signaling regulation mechanism between HER2 and
ABCG2. Of course, all the above speculated regulation
pathways need to be certificated by further study.
Conclusion
Our study demonstrates the expression of ABCG2 in nor-
mal ductal epithelia and in the tumor cells of invasive duc-
tal carcinoma of breast. Its expression is correlated
significantly with that of HER2, lymph node metastasis,
and clinical stage in invasive ductal breast cancer. These
findings suggest that ABCG2 not only is one of the drug-
resistance genes, but also is a novel potential bio-marker
which can predict biological behavior, clinical progression,
prognosis and chemotherapy effectiveness. Further investi-
gation on the molecular mechanism of possible regulation
relationships between them is warranted, especially on the
PI3K/Akt signaling pathway.
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